Stay updated with breaking news from Eric Widera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WASHINGTON (AP) — Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.
Two similar Alzheimer’s drugs are likely to be on the market and accessible for Medicare patients sometime in 2024.
Eli Lilly's experimental Alzheimer's drug donanemab can modestly slow the worsening of the disease by about four to seven months, according to researchers.
New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening
A second drug may join the Alzheimer’s treatment Leqembi on the market by the end of the year: Eli Lilly’s donanemab. Lilly said in a news release that it had completed its US Food and Drug Administration submission for the drug, and expects regulatory action by year’s end.